Gasolina-RD Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, acts as a prokinetic agent by enhancing gastrointestinal motility and accelerating gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving efficacy and patient compliance by reducing dosing frequency. Gasolina-RD Capsule SR is indicated for patients requiring both acid suppression and prokinetic therapy, particularly those with delayed gastric emptying and persistent reflux symptoms unresponsive to monotherapy. It should be administered under medical supervision, considering potential contraindications such as hypersensitivity to components, and used cautiously in patients with hepatic impairment or cardiac conditions. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Drug interactions should be monitored, especially with medications metabolized via the cytochrome P450 system.